Ipca Labs net profit rises 35 percent to Rs 267.56 crore in Q3
New Delhi: Drug firm Ipca Laboratories on Thursday reported a 35.44 percent rise in consolidated net profit to Rs 267.56 crore for the third quarter ended December 2020, on the back of robust sales in domestic and international markets. The company had posted a net profit of Rs 197.54 crore for the same period of the previous fiscal, Ipca Labs said in a BSE filing.
Its consolidated total income stood at Rs 1,425.21 crore for the quarter under consideration. It was Rs 1,230.99 crore for in the year-ago period, it added.
Indian formulations income was up 8 per cent at Rs 523.16 crore for the quarter ended December this fiscal, and export income rose 21 per cent to Rs 709.25 crore, the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.